A Phase 3 interventional study of TNX-102 SL Tablet, 2.8mg and Placebo SL Tablet in Fibromyalgia, Myofascial Pain Syndromes and Muscular Diseases, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-07.
Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.
Among the 369 studies in Fibromyalgia with a site in United States, this one is the 23rd largest by enrollment of the 320 interventional ones that give a count, is one of 12 that started in 2015, is one of 55 in phase 3, and was the 204th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Spaulding Rehabilitation Hospital · Sites in United States
Ages 21–65
Pulkit Grover · Sites in United States
Ages 18–65
Theranica · Sites in United States, Israel
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 61 · Phase 3 64 · Phase 4 24
First in 1994; this study’s year is marked. 12 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 519 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 72 across the 320 interventional studies, 200 across the 47 observational. Of the 276 that completed or were terminated, 116 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 369 have an industry lead sponsor. The 10 most frequent:
Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Tonix Pharmaceuticals, Inc. has 8 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
29 of the studies in Fibromyalgia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT07116278University of California, San FranciscoTMS-EEG Biomarkers for Chronic Pain | 2026-12 |
| NCT04949100Paul CrawfordMicrocurrent for Fibromyalgia | 2026-12 |
| NCT07525063Duke UniversityPain & Reward Neuromodulation of CNS Circuits | 2026-12 |
| NCT06552728University of California, IrvineThe Effects of Energy Healing in Fibromyalgia | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 369 studies in Fibromyalgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The use of low-dose CBP dosed nightly at bedtime for FM was supported by the results of Tonix' TNX-CY-F202 Phase 2b study (also referred to as the BESTFIT Study). The TNX-CY-F202 study provided evidence that TNX-102 SL 2.8 mg dosed nightly results in beneficial effects upon pain, sleep and other FM symptomatology.
The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks
Drug: TNX-102 SL Tablet, 2.8mg
1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
Drug: Placebo SL Tablet
Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
Also known as: Low dose cyclobenzaprine sublingual tablets
Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
Also known as: Placebo sublingual tablets
Proportion of Patients With ≥30% Pain Improvement
The primary efficacy endpoint is the proportion of patients with a ≥30% improvement (responder criteria) from baseline to Week 12 in the weekly mean of the daily self-reported 24-hour recall average pain intensity score using an 11-point (0-10) NRS. Scores range from 0 (no pain) to 10 (worst possible pain).
Time frame: Day 1, Week 12
Patient's Global Impression of Change (PGIC)
Proportion of patients with a PGIC rating of 1 ("very much improved") or 2 ("much improved") at Week 12. The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates the highest level of worsening.
Time frame: Week 12
Change From Baseline to Week 12 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score
The FIQR is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.
Time frame: Day 1, Week 12
Change From Baseline to Week 12 in the FIQR Function Domain Score
The FIQR is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.
Time frame: Day 1, Week 12
Patient Reported Outcomes Measurement System (PROMIS) Sleep Disturbance
Change from baseline in the PROMIS score for sleep disturbance at Week 12. The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10. Lower T-scores indicate less sleep disturbance.
Time frame: Day 1, Week 12
Weekly Average of Daily Sleep Quality Diary
Change from Baseline in the weekly average of the daily diary assessment of sleep quality at Week 12. Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).
Time frame: Baseline (Day -7 to Day -1), Week 12
Patient Reported Outcomes Measurement System (PROMIS) Fatigue
Change from Baseline in the PROMIS score for fatigue at Week 12. The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10. Lower T-scores indicate less fatigue.
Time frame: Day 1, Week 12
Weekly Average of Daily Pain Diary
Change from baseline to Week 12 in the weekly average of the daily self-reported average pain severity score using an 11-point (0-10) NRS. Scores range from 0 (no pain) to 10 (worst possible pain).
Time frame: Baseline (Day -7 to Day -1), Week 12
| Milestone | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg |
|---|---|---|
| Started | 257 | 262 |
| Completed | 222 | 203 |
| Not completed | 35 | 59 |
The primary efficacy endpoint is the proportion of patients with a ≥30% improvement (responder criteria) from baseline to Week 12 in the weekly mean of the daily self-reported 24-hour recall average pain intensity score using an 11-point (0-10) NRS. Scores range from 0 (no pain) to 10 (worst possible pain).
| Participants | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg |
|---|---|---|
| Proportion of Patients With ≥30% Pain Improvement | 58 | 75 |
Proportion of patients with a PGIC rating of 1 ("very much improved") or 2 ("much improved") at Week 12. The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates the highest level of worsening.
| Participants | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg |
|---|---|---|
| Patient's Global Impression of Change (PGIC) | 42 | 62 |
The FIQR is a validated questionnaire. Scores on the symptoms domain range from 0 to 100 where a higher score means worse outcome.
| units on a scale | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg |
|---|---|---|
| Change From Baseline to Week 12 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score | -8.2 ± 1.13 | -14.1 ± 1.14 |
The FIQR is a validated questionnaire. Scores on the function domain range from 0 to 90 where a higher score means worse outcome.
| units on a scale | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg |
|---|---|---|
| Change From Baseline to Week 12 in the FIQR Function Domain Score | -4.4 ± 1.15 | -10.3 ± 1.16 |
Change from baseline in the PROMIS score for sleep disturbance at Week 12. The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10. Lower T-scores indicate less sleep disturbance.
| T-score | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg |
|---|---|---|
| Patient Reported Outcomes Measurement System (PROMIS) Sleep Disturbance | -4.7 ± .53 | -8.0 ± .54 |
Change from Baseline in the weekly average of the daily diary assessment of sleep quality at Week 12. Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS. Scores range from 0 (best possible sleep) to 10 (worst possible sleep).
| units on a scale | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg |
|---|---|---|
| Weekly Average of Daily Sleep Quality Diary | -1.0 ± 0.11 | -1.8 ± 0.11 |
Change from Baseline in the PROMIS score for fatigue at Week 12. The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10. Lower T-scores indicate less fatigue.
| T-score | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg |
|---|---|---|
| Patient Reported Outcomes Measurement System (PROMIS) Fatigue | -4.2 ± .47 | -6.4 ± .47 |
Change from baseline to Week 12 in the weekly average of the daily self-reported average pain severity score using an 11-point (0-10) NRS. Scores range from 0 (no pain) to 10 (worst possible pain).
| units on a scale | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg |
|---|---|---|
| Weekly Average of Daily Pain Diary | -1.0 ± 0.11 | -1.5 ± 0.11 |
Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo SL Tablet | 0/256 (0%) | 4/256 (1.6%) | 17/256 (6.6%) |
| TNX-102 SL Tablet, 2.8 mg | 0/262 (0%) | 3/262 (1.1%) | 132/262 (50.4%) |
| Event | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg |
|---|---|---|
| DizzinessNervous system disorders | 1/256 | 0/262 |
| PresyncopeNervous system disorders | 1/256 | 0/262 |
| Atrial FibrillationCardiac disorders | 1/256 | 0/262 |
| Non-cardiac Chest PainGeneral disorders | 1/256 | 0/262 |
| Foot FractureInjury, poisoning and procedural complications | 1/256 | 0/262 |
| SeizureNervous system disorders | 0/256 | 1/262 |
| PneumoniaInfections and infestations | 0/256 | 1/262 |
| Suicide AttemptPsychiatric disorders | 0/256 | 1/262 |
| Event | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg |
|---|---|---|
| Hypoaesthesia OralGastrointestinal disorders | 2/256 | 105/262 |
| GlossodyniaGastrointestinal disorders | 4/256 | 24/262 |
| Paraesthesia OralGastrointestinal disorders | 3/256 | 20/262 |
| Product Taste AbnormalProduct Issues | 2/256 | 16/262 |
| FatigueGeneral disorders | 6/256 | 15/262 |
| Age, Continuous(years) | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg | Total |
|---|---|---|---|
| Mean | 47.8 ± 11.20 | 47.8 ± 11.16 | 47.8 ± 11.17 |
| Sex: Female, Male(Participants) | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg | Total |
|---|---|---|---|
| Female | 247 | 252 | 499 |
| Male | 10 | 10 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 21 | 31 | 52 |
| Not Hispanic or Latino | 236 | 231 | 467 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 4 |
| Asian | 5 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 27 | 11 | 38 |
| White | 221 | 242 | 463 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 1 | 3 | 4 |
| Region of Enrollment(participants) | Placebo SL Tablet | TNX-102 SL Tablet, 2.8 mg | Total |
|---|---|---|---|
| United States | 257 | 262 | 519 |
The record gives a start of Apr 2015, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2025, 8 years 5 months after primary completion. A results delay was requested in Dec 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclobenzaprine